Biocon Limited (NSE:BIOCON)

Market Cap	512.17B
Revenue (ttm)	164.76B
Net Income (ttm)	4.86B
Shares Out	1.33B
EPS (ttm)	3.91
PE Ratio	98.27
Forward PE	51.02
Dividend	0.50 (0.13%)
Ex-Dividend Date	Jul 4, 2025

Volume	4,551,481
Average Volume	5,440,764
Open	383.00
Previous Close	383.80
Day's Range	375.55 - 386.90
52-Week Range	291.00 - 424.95
Beta	0.24
RSI	45.88
Earnings Date	Nov 11, 2025

About Biocon

Biocon Limited, together with its subsidiaries, manufactures and sells biotechnology products and research services in India, the United States, Ireland, rest of the European Union, and internationally. It operates through Generics, Biosimilars, and Research segments. The company offers generic formulations and API products, including cardiovascular, anti-diabetics, obesity, multiple sclerosis, anti-fungal, anti-cancer, immunosuppressants, and specialty molecules; and biosimilars products consisting of pegfilgrastim, trastuzumab, bevacizumab, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1978
• Employees: 16,315
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BIOCON

Financial Performance

In 2024, Biocon's revenue was 152.62 billion, an increase of 3.43% compared to the previous year's 147.56 billion. Earnings were 10.13 billion, a decrease of -0.90%.